JACC advances最新文献

{"title":"Progression of Ascending Aortic Dimensions in Masters Endurance Athletes","authors":"Nathaniel Moulson MD, MHA , Noah D. Boroditsky BSc , Julien Wiese BSc , Reid A. Mitchell MSc , Mark J. Haykowsky PhD , Stephen J. Foulkes PhD , James Roberts MD , Saul Isserow MBBCh , Barbara N. Morrison PhD , James McKinney MD","doi":"10.1016/j.jacadv.2025.102163","DOIUrl":"10.1016/j.jacadv.2025.102163","url":null,"abstract":"","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102163"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total Atrial Conduction Time as a Predictor of Left Atrial Functional Recovery in Atrial Fibrillation","authors":"Hikari Seki MD ,&nbsp;Koki Nakanishi MD ,&nbsp;Masao Daimon MD ,&nbsp;Kazutoshi Hirose MD ,&nbsp;Kentaro Iwama MD ,&nbsp;Yasuhiro Mukai MD ,&nbsp;Yuriko Yoshida MD ,&nbsp;Yuko Yamamoto MD ,&nbsp;Megumi Hirokawa MD ,&nbsp;Tomoko Nakao MD ,&nbsp;Tsukasa Oshima MD ,&nbsp;Takumi Matsubara MD ,&nbsp;Yu Shimizu MD ,&nbsp;Gaku Oguri MD ,&nbsp;Toshiya Kojima MD ,&nbsp;Eriko Hasumi MD ,&nbsp;Katsuhito Fujiu MD ,&nbsp;Hiroyuki Morita MD ,&nbsp;Makoto Kurano MD ,&nbsp;Norihiko Takeda MD","doi":"10.1016/j.jacadv.2025.102151","DOIUrl":"10.1016/j.jacadv.2025.102151","url":null,"abstract":"<div><h3>Background</h3><div>Catheter ablation (CA) leads to the recovery of left atrial (LA) function in patients with atrial fibrillation (AF), although the degree varies substantially among individuals. PA-TDI duration, the time delay between the P-wave on the electrocardiogram to the peak A'-wave on tissue-Doppler imaging of the lateral LA wall is an echocardiographic measure that reflects structural and electrical LA remodeling.</div></div><div><h3>Objectives</h3><div>The objective of the study was to investigate whether the preprocedural PA-TDI duration could predict LA functional recovery after CA.</div></div><div><h3>Methods</h3><div>We studied 109 AF patients in sinus rhythm at preprocedural echocardiography, who underwent their first CA. PA-TDI duration was measured by tissue Doppler imaging from the apical four-chamber view. Speckle-tracking echocardiography was performed before and 6 months after CA to evaluate LA reservoir strain (LARS).</div></div><div><h3>Results</h3><div>The median (25th–75th percentile) PA-TDI duration was 144 (128-162) ms. There was no significant difference in age, sex, and AF risk factors between patients with longer PA-TDI duration (≥144 ms) and those with shorter PA-TDI duration (&lt;144 ms). The median follow-up was 465 (273-746) days. LARS was significantly improved at 6 months after CA (29.7% ± 7.9% to 32.1% ± 6.7%; <em>P</em> &lt; 0.001). Preprocedural PA-TDI duration was significantly associated with LARS at 6 months after CA independent of AF type, baseline LARS, and recurrent AF (standardized beta −0.20; 95% CI: −0.10 to −0.01; <em>P</em> = 0.013). Combination of baseline LARS and PA-TDI duration provided enhanced predictive value for postprocedural LA function (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The measurement of PA-TDI duration provided valuable information for LA functional recovery in AF patients who underwent CA.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102151"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Density Lipoprotein Cardioprotection Function Deteriorates as Women Transition Through Menopause","authors":"Samar R. El Khoudary PhD, MPH ,&nbsp;James Matuk PhD ,&nbsp;Maria Brooks PhD ,&nbsp;Dan McConnell PhD ,&nbsp;Sybil Crawford PhD ,&nbsp;Ziyuan Wang PhD ,&nbsp;Imke Janssen PhD ,&nbsp;Daniel Rader MD","doi":"10.1016/j.jacadv.2025.102131","DOIUrl":"10.1016/j.jacadv.2025.102131","url":null,"abstract":"<div><h3>Background</h3><div>Women show a rise in high-density lipoprotein cholesterol efflux capacity (CEC) as they traverse menopause. Whether this rise is associated with a lower risk of cardiovascular disease overtime is not clear.</div></div><div><h3>Objectives</h3><div>The authors tested whether CEC association with subclinical vascular health, measured using a composite subclinical vascular health score based on levels of carotid intima-media thickness, carotid-femoral pulse wave velocity, and presence of coronary artery calcium score (&gt;10), varies by time relative to the final menstrual period (FMP).</div></div><div><h3>Methods</h3><div>279 women (baseline age 51 ± 2.8 years; 68.5% White) who had CEC and outcome measures were included. The subclinical vascular health measures were related to CEC through a Bayesian hierarchical linear mixed effects model using the latent composite measure as the outcome, and time relative to FMP, CEC, and their interaction as explanatory variables. Differences by racial subgroups were explored.</div></div><div><h3>Results</h3><div>Higher CEC was associated with a lower composite subclinical measure of vascular health at the time of the FMP. In both unadjusted and adjusted models, the inferred interaction effect (posterior probability &gt;0.99) implies that the pre-FMP protective association of CEC diminishes after FMP. This was consistent across all components of the composite score. In Black women, the protective association of CEC diminished more rapidly compared to White women (posterior probability &gt;0.90).</div></div><div><h3>Conclusions</h3><div>In women, higher CEC is associated with a lower risk of subclinical vascular health only before menopause. Higher CEC is not a consistent indicator of greater cardiovascular disease protection in women traversing menopause.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102131"},"PeriodicalIF":0.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertensive Disorders of Pregnancy in Patients With Cardiac Disease","authors":"Maura Jones Pullins MD ,&nbsp;Johanna Quist-Nelson MD ,&nbsp;Matthew Fuller MS ,&nbsp;Elizabeth Volz MD ,&nbsp;Sarah Snow MD ,&nbsp;Ashraf S. Habib MBBCh, MSc, MHSc ,&nbsp;Jerome Federspiel MD, PhD ,&nbsp;Kim Boggess MD ,&nbsp;Marie-Louise Meng MD","doi":"10.1016/j.jacadv.2025.102130","DOIUrl":"10.1016/j.jacadv.2025.102130","url":null,"abstract":"<div><h3>Background</h3><div>Pregnant patients with cardiovascular disease (CVD) face increased risk of hypertensive disorders of pregnancy (HDP) and preterm delivery, yet data are limited regarding the degree of risk and impact of HDP on gestational age at delivery.</div></div><div><h3>Objectives</h3><div>The objective of the study was to examine the HDP risk and impact on gestational age at delivery in patients with CVD.</div></div><div><h3>Methods</h3><div>This retrospective cohort study used the Premier Healthcare Database and included patients &gt;18 years who delivered between October 1, 2015, and December 31, 2020. Patients with CVD were categorized into the following 6 subtypes: congenital, ischemic, aortic pathology, pulmonary hypertension (HTN), cardiomyopathy, and valvular disease. Primary outcome was odds of HDP (gestational HTN or pre-eclampsia); Secondary outcome was gestational age at delivery. Multivariable mixed effects regression models were used to estimate adjusted outcomes, adjusting for CVD subtype, &gt;1 CVD subtype present, demographics, hospital characteristics, and comorbidities.</div></div><div><h3>Results</h3><div>Among 4,606,247 obstetric patients, 20,021 had CVD. HDP risk varied by CVD subtype, lowest in those with congenital heart disease (adjusted OR [aOR]: 0.9; 95% CI: 0.8-1.0) and highest in those with pulmonary HTN (aOR: 1.5; 95% CI: 1.3-1.8) and cardiomyopathy (aOR: 1.5; 95% CI: 1.4-1.6). Patients with CVD delivered earlier than those without CVD, even in the absence of HDP (36.4-38.0 weeks vs 38.4 weeks). Among those with HDP, patients with severe pre-eclampsia with CVD, delivered earlier than those without CVD (33.1-34.6 weeks vs 35.5 weeks).</div></div><div><h3>Conclusions</h3><div>Odds of HDP and delivering at an earlier gestational age differs across CVD subtypes, notably higher in those with pulmonary HTN and cardiomyopathy, emphasizing the need for individualized counseling.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102130"},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145060598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trials on Timing of Cardiovascular Medication Administration","authors":"Manan Pareek MD, MSc, PhD ,&nbsp;Niklas Dyrby Johansen MD, PhD ,&nbsp;Sine Højlund Christensen MSc ,&nbsp;Anna Meta Dyrvig Kristensen MD ,&nbsp;Majid Afzal MD ,&nbsp;Johanna Maria Christina Frary MD ,&nbsp;Muthiah Vaduganathan MD, MPH ,&nbsp;Michael Hecht Olsen MD, PhD, DMSc ,&nbsp;Pradeesh Sivapalan MD, PhD ,&nbsp;Jens Ulrik Stæhr Jensen MD, PhD ,&nbsp;Deepak L. Bhatt MD, MPH, MBA ,&nbsp;Tor Biering-Sørensen MD, MSc, MPH, PhD","doi":"10.1016/j.jacadv.2025.102147","DOIUrl":"10.1016/j.jacadv.2025.102147","url":null,"abstract":"<div><div>The incidence of certain disease events such as myocardial infarction, stroke, aortic rupture, and sudden cardiac death is affected by the time of day. It is thus theorized that synchronization of medication timing with circadian rhythmicity (or at the minimum, clock time) may improve treatment efficacy and/or reduce the risk of serious adverse events. We launched the C³ (Cardiovascular Circadian Chronotherapy) trial concept to efficiently conduct randomized, controlled, clinical outcome trials of the timing of medication administration. This concept takes advantage of the Danish nationwide administrative health registries for participant identification and collection of baseline and follow-up data as well as the mandatory governmental electronic letter system. Although many of these interventions may only provide small effect sizes, any positive effects from simple changes in the timing of drug administration could potentially lead to large, worldwide prognostic improvements.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102147"},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pericardial Disease-Related Mortality in the United States","authors":"Taimor Mohammed Khan MBBS ,&nbsp;Muhammad Moiz Nasir MBBS ,&nbsp;Saad Ahmed Waqas MBBS ,&nbsp;Muhammad Salik Uddin MBBS ,&nbsp;Aymen Ahmed MBBS ,&nbsp;Muhammad Omar MBBS ,&nbsp;Raheel Ahmed MBBS, PhD ,&nbsp;Hasan Fareed Siddiqui MBBS","doi":"10.1016/j.jacadv.2025.102157","DOIUrl":"10.1016/j.jacadv.2025.102157","url":null,"abstract":"<div><h3>Background</h3><div>Despite advancements in medical management, pericardial disease (PD)–related mortality is on the rise, yet comprehensive data on its prevalence and mortality rates in the United States remains limited.</div></div><div><h3>Objectives</h3><div>This study aimed to analyze PD-related mortality trends in the United States from 1999 to 2019, focusing on demographic variations based on sex, age, race/ethnicity, geographical regions, and urban–rural distinctions.</div></div><div><h3>Methods</h3><div>A descriptive analysis was conducted using death certificate data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database. Mortality rates were assessed among adults aged ≥25 years diagnosed with PD, using International Classification of Diseases-10th Revision codes. Crude mortality rates and age-adjusted mortality rates (AAMRs) were calculated, and temporal trends were analyzed using joinpoint regression.</div></div><div><h3>Results</h3><div>A total of 87,285 PD-related deaths were recorded during this period. AAMR initially decreased from 2.36 in 1999 to 1.70 in 2012, with an annual percentage change of −2.74% (<em>P</em> &lt; 0.001) However, this trend reversed, as AAMR increased significantly to 2.04 by 2019, with an annual percentage change of +2.94% (<em>P</em> &lt; 0.001). Higher mortality rates were observed among males, older adults (≥65 years), and non-Hispanic Black or African American individuals. The Western region exhibited the highest AAMR, whereas rural areas showed slightly elevated mortality rates compared to urban areas after 2012.</div></div><div><h3>Conclusions</h3><div>These findings underscore a resurgence in PD-related mortality, highlighting the urgent need for improved public health strategies to address this growing burden, particularly among vulnerable populations.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102157"},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145060433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Neighborhood Factors on Heart Failure Outcomes","authors":"Timothy Bober MD, MS ,&nbsp;Emily N. Guhl MD ,&nbsp;Scott Rothenberger PhD ,&nbsp;Kwonho Jeong MS ,&nbsp;Kaleab Z. Abebe PhD ,&nbsp;Julia Holber MD ,&nbsp;Amy M. Anderson MS, LPC ,&nbsp;Jared W. Magnani MD, MSc ,&nbsp;Amber E. Johnson MD, MS, MBA ,&nbsp;Bruce L. Rollman MD, MPH, MBA","doi":"10.1016/j.jacadv.2025.102146","DOIUrl":"10.1016/j.jacadv.2025.102146","url":null,"abstract":"<div><h3>Background</h3><div>Few studies have examined the impact of neighborhood-level factors on outcomes for patients with heart failure with reduced ejection fraction (HFrEF).</div></div><div><h3>Objectives</h3><div>The purpose of this study was to understand the impact of neighborhood factors on readmission and mortality risk hospitalized patients with HFrEF.</div></div><div><h3>Methods</h3><div>We analyzed data from the Hopeful Heart Trial that evaluated the impact of blended collaborative care for treating HFrEF and depression among patients discharged from 8 Pittsburgh-area hospitals from March 2014 to October 2017. Using patients' home address at discharge to determine neighborhood Walk Score (WS; 0-100 scale) and Area Deprivation Index (ADI; 0-100), we examined the incidence of 12-month all-cause and cardiovascular-related hospital readmissions and vital status up to 5 years postdischarge through June 2022 using multivariable-adjusted Cox proportional hazards models.</div></div><div><h3>Results</h3><div>Hopeful Heart enrolled 756 people with HFrEF (baseline mean age 64.0, 44% female, 73% White race, 28% ± 9.1% mean left ventricular ejection fraction, mean 9-Item Patient Health Questionnaire score 12 ± 5.7, median WS 69 (IQR: 49-88), and median ADI 12 (IQR: 10-15) and followed them for a median of 57.7 months (IQR: 25.0-68.4). Individuals from the least walkable neighborhoods experienced greater 12-month all-cause mortality (HR: 1.70 [95% CI: 1.11-2.61]; <em>P</em> = 0.016), while those from the most deprived neighborhoods had higher 12-month cardiovascular-related hospital readmission (HR: 1.39 [95% CI: 1.09-1.78]; <em>P</em> = 0.008). Neither WS nor ADI predicted 12-month all-cause readmission and cardiovascular-related mortality or 5-year all-cause mortality.</div></div><div><h3>Conclusions</h3><div>Among recently hospitalized HFrEF patients, neighborhood factors affect 12-month rehospitalization and mortality risk but not 5-year mortality. (Blended Collaborative Care for Heart Failure and Co-Morbid Depression; <span><span>NCT02044211</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102146"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145057386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Trial of a Resilience-Building Intervention in Adult Outpatients With Congenital Heart Disease","authors":"Jill M. Steiner MD, MS ,&nbsp;Arisa Rei Marshall BS ,&nbsp;Lyndia Brumback PhD ,&nbsp;Yixuan Connie Zhang BA ,&nbsp;Thomas M. Glenn MD ,&nbsp;Adrienne H. Kovacs PhD ,&nbsp;Karen K. Stout MD ,&nbsp;Chris T. Longenecker MD ,&nbsp;Joyce P. Yi-Frazier PhD ,&nbsp;Abby R. Rosenberg MD, MS, MA","doi":"10.1016/j.jacadv.2025.102164","DOIUrl":"10.1016/j.jacadv.2025.102164","url":null,"abstract":"<div><h3>Background</h3><div>Interventions are needed to address growing concerns regarding poor psychosocial and mental health in adult congenital heart disease (ACHD). Strengthening patients' resilience is one proposed pathway, given its ability to improve quality of life in other patient populations.</div></div><div><h3>Objectives</h3><div>The objective of this study was to evaluate feasibility and efficacy of a resilience-building intervention in ACHD.</div></div><div><h3>Methods</h3><div>We conducted a clinical trial of outpatients with moderate or complex ACHD, randomized to receive a cognitive-behavioral intervention (Promoting Resilience in Stress Management [PRISM]) vs usual care. Participants completed surveys at randomization and 3 months. We evaluated feasibility using enrollment and retention rates. We evaluated PRISM's effect on the primary outcome (change in self-reported resilience) and exploratory outcomes using linear regression adjusted for baseline measurement.</div></div><div><h3>Results</h3><div>We enrolled 78 patients from March 2023 to April 2024. Patients were randomized to treatment (PRISM; n = 40, age 36 ± 11 years; 50% female; 58% self-reported White race/ethnicity) vs control (n = 38, age 40 ± 12 years; 74% female; 79% White). Over three-quarters of participants randomized to treatment completed PRISM (80%) and follow-up measures. Of controls, 35/38 (92%) completed follow-up measures. Resilience scores at 3 months were higher in the treatment group (n = 30, 30.1 ± 8.1) compared to control (n = 35, 28.7 ± 5.8); this difference was not statistically significant. Mean quality of life at follow-up was significantly higher in the treatment group (79 ± 14 vs 73 ± 14; 95% CI: 0.8-12.7; <em>P</em> = 0.03). Program feedback was positive.</div></div><div><h3>Conclusions</h3><div>This study demonstrates intervention feasibility with modifications. Although we did not demonstrate efficacy, participants were engaged and provided valuable feedback, suggesting value in ACHD. (Assessing and Promoting Resilience in Patients With Adult Congenital Heart Disease [PRISMACHD]; <span><span>NCT04738474</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102164"},"PeriodicalIF":0.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145049139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Precapillary Component of Pulmonary Pressure in Tricuspid Transcatheter Edge-to-Edge Repair","authors":"Antonio Sisinni MD ,&nbsp;Xavier Freixa MD, PhD ,&nbsp;Dabit Arzamendi MD, PhD ,&nbsp;Vanessa Moñivas Palomero MD, PhD ,&nbsp;Fernando Carrasco-Chinchilla MD, PhD ,&nbsp;Manuel Pan MD, PhD ,&nbsp;Luis Nombela-Franco MD, PhD ,&nbsp;Isaac Pascual MD, PhD ,&nbsp;Tomás Benito-González MD ,&nbsp;Rodrigo Estévez-Loureiro MD, PhD","doi":"10.1016/j.jacadv.2025.102153","DOIUrl":"10.1016/j.jacadv.2025.102153","url":null,"abstract":"","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102153"},"PeriodicalIF":0.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145049165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Life’s Simple 7 and Life’s Essential 8 With Risk of Heart Failure","authors":"Inge G. van Loon MSc ,&nbsp;Yvonne T. van der Schouw PhD ,&nbsp;M. Louis Handoko MD, PhD ,&nbsp;W.M. Monique Verschuren PhD ,&nbsp;Alicia Uijl PhD","doi":"10.1016/j.jacadv.2025.102127","DOIUrl":"10.1016/j.jacadv.2025.102127","url":null,"abstract":"<div><h3>Background</h3><div>Better cardiovascular health (CVH) lowers risk of heart failure (HF). CVH can be quantified using Life’s Essential 8 (LE8), a score consisting of 8 health factors and behaviors.</div></div><div><h3>Objectives</h3><div>The authors assessed the association between LE8 and risk for HF, and compared LE8 with its predecessor, Life’s Simple 7 (LS7).</div></div><div><h3>Methods</h3><div>We included 37,803 participants from the EPIC-NL (European Prospective Investigation into Cancer and Nutrition-Netherlands) cohort. The LE8 score ranged from 0 to 100 and was categorized into low (0-49), moderate (50-79), and high (80-100) CVH. CVH classification was compared between LS7 and LE8 scoring. Adjusted Cox proportional hazard models were used to assess LE8 score with risk of HF, and CVH reclassification from LS7 to LE8.</div></div><div><h3>Results</h3><div>Participants were predominantly female (74%), with a median age of 52 years (Q1-Q3: 42-58). Compared to low CVH (4%), those with high CVH (21%) had an 82% lower risk of developing HF (HR: 0.18; 95% CI: 0.12-0.26). CVH classification differed substantially between LE8 and LS7, with 75% vs 36% having moderate CVH, respectively, which could be attributed to an upward shift (90%) of participants from LS7 low CVH to LE8 moderate CVH. A graded, nonlinear association with risk for HF was observed for LE8, especially for moderate CVH scores.</div></div><div><h3>Conclusions</h3><div>LS7 and LE8 differ in scoring and CVH classification. While a strong inverse association exists between LE8 score classification and HF risk, the association is graded over the whole LE8 range, suggesting that nuances may be overlooked when using the proposed CVH classification for exploring HF risk.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102127"},"PeriodicalIF":0.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145049134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}